Strategic Signals Weekly

Karyopharm Therapeutics entered a Forbearance Agreement and issued $20 million in convertible preferred stock to certain lenders, aiming to gain time to advance its myelofibrosis program, negotiate with lenders, pursue strategic alternatives, or raise equity capital. The preferred stock includes repurchase rights that can be triggered by specific FDA actions or the company's withdrawal of its supplemental new drug application for selinexor in myelofibrosis.

Cardiff Oncology, Inc. and Nerviano Medical Sciences, S.r.l. entered into a settlement agreement to resolve litigation concerning inventorship and performance under their 2017 license agreement for onvansertib. Concurrently, they amended the license agreement, updating exclusivity, royalty terms, development milestone obligations related to Cardiff's upcoming Phase 3 program, and governance provisions. No monetary payment was made by either party in connection with the settlement.

Drug: onvansertib · Partner: Nerviano Medical Sciences, S.r.l.

CapsoVision, Inc. entered into a securities purchase agreement for a registered direct offering, selling 3,163,444 shares of common stock at $5.69 per share. This offering is expected to generate approximately $18 million in gross proceeds. The funds will be used for general corporate purposes, including sales and marketing, research and development, and working capital, with existing stockholders participating as purchasers.

Lisata Therapeutics, Inc. completed the acquisition of Marea Therapeutics, Inc. through a merger, issuing common stock and convertible preferred stock to Marea's stockholders. This merger, combined with a subsequent private placement (PIPE) involving new investors, significantly restructured the company's equity. Following these transactions, new investors will hold approximately 38.07% of the combined company, former Marea equityholders 59.54%, and pre-transaction Lisata stockholders 2.39%.

Surgery Partners, Inc. completed the disposition of its Mountain View Hospital and Idaho Falls Community Hospital operations to Intermountain Health on September 14, 2026. The company received approximately $796.6 million in aggregate consideration, which it intends to use primarily to pay down debt. Pro forma financial statements reflecting the transaction are included in the filing.

Beta Bionics, Inc. entered into an underwriting agreement for a public offering of 7,652,175 shares of common stock and 1,043,484 pre-funded warrants, expecting gross proceeds of approximately $150.0 million. The company plans to use the net proceeds for general corporate purposes, including commercialization of Mint™, manufacturing expansion, research and development, clinical development, product enhancements, and potential strategic opportunities.

Aethlon Medical, Inc. announced a merger with North Immunology, Inc., which will result in North Immunology stockholders owning approximately 95.25% of the combined company. Concurrently, North Immunology secured a private placement of approximately $180 million from institutional and accredited investors. A minimum of $175 million in proceeds from this financing is a closing condition for the merger, which will see the combined entity operate under the North Immunology name and be led by its current CEO.